TABLE 5.

Subgroup analysis of main outcomes.

Outcome or subgroup	Studies	Participants		MD/RR (95% CI)	Z	P	Heterogeneity
							I2	Ph
1. HFES	21	2,185		1.24 [1.19–1.30]	9.85	<0.00001	11	0.31
SFI	8	827		1.19 [1.12–1.28]	5.29	<0.00001	0	0.76
SGMI	3	290		1.43 [1.23–1.66]	4.62	<0.00001	0	0.86
QLQX	2	300		1.25 [1.08–1.43]	5.05	<0.00001	65	0.09
SMI	8	648		1.28 [1.17–1.41]	5.3	<0.00001	37	0.13
Treatment duration
≤14 days	18	1,525		1.24 [1.18–1.31]	8.13	<0.00001	15	0.27
>14 days	3	660		1.25 [1.15–1.36]	5.09	<0.00001	28	0.25
LVEF
LVEF ≤50%	6	556		1.22 [1.13–1.31]	5.27	<0.00001	0	0.87
LVEF not limited	15	1,629		1.26 [1.19–1.34]	7.55	<0.00001	30	0.13
2. LVEF	23	2,281		5.80 [4.86–6.74]	10.45	0.002	89	<0.00001
Different drugs
SFI	10	868		4.27 [3.65–5.44]	8.93	<0.00001	42	0.08
SGMI	4	414		5.90 [4.83–6.98]	10.31	<0.00001	0	0.54
SMI	6	499		6.12 [4.22–8.02]	6.31	<0.00001	95	<0.00001
QLQX	2	420		9.62 [8.36–10.88]	15.02	<0.00001	0	0.57
YXST	1	80		7.08 [-5.73–19.90]	1.08	0.28	86	0.007
Treatment duration
≤14 days	20	1781		5.24 [4.23–6.25]	10.13	<0.00001	90	<0.00001
>14 days	3	500		9.47 [7.02–11.92]	7.57	<0.00001	61	0.05
LVEF
LVEF ≤50%	10	903		4.63 [3.08–6.19]	5.83	<0.00001	76	<0.0001
LVEF not limited	13	1,378		6.67 [5.72–7.62]	13.74	<0.00001	85	<0.00001